Pharma companies are currently experiencing unprecedented challenges as a result of external factors such as geopolitics, the adoption of new modalities, rapidly changing technologies including digital ones, and also regulatory changes. In order to overcome these challenges, the pharmaceutical industry must accelerate and embrace new technologies, approaches and thinking. Hence to grow and...

The 2026 ISPE Facilities of the Future Conference is set to take place 2–3 February in San Diego, California, USA. The conference will focus on the future of pharmaceutical manufacturing, with dedicated technical tracks on compliance and quality;...

The 2025 ISPE International Honor Awards were held during the Membership Meeting and Awards Lunch during the 2025 ISPE Annual Meeting & Expo in Charlotte, North Carolina, USA. The ceremony recognized ISPE members and contributors whose dedication and service exemplify what it means to Shape the Future of Pharma™. The Emerging Leader Member of the Year Award was presented to Ryan Mazur and...

In the biopharmaceutical industry, the world is changing faster than buildings can be built. Companies are being asked to deliver breakthrough therapies, expand capacity, diversify modality pipelines, decarbonize operations, meet ever-shifting regulatory expectations, and stay globally competitive—all while maintaining reliability, safety, and cost control.

The evolution of pharmaceutical manufacturing has progressed through several stages—from manual drug compounding to fully automated lines with rigorous quality control. Today, a new era—Pharma 4.0™—is unfolding, offering both transformative opportunities and complex challenges driven by market needs, regulatory requirements, and rapid digital innovation.

Mike Martin, President and CEO of ISPE, recently connected with Nicholas Capman, President and CEO of The FDA Group, a podcast that discusses current regulatory complexities facing the life science industry and explore innovative ways to overcome those challenges.

Pharmaceutical manufacturing faces mounting pressure to comply with stringent regulatory requirements while maintaining the highest standards of quality, speed, and efficiency. As digital transformation revolutionizes industries, artificial intelligence (AI) is emerging as a critical driver of change in reshaping how pharmaceutical companies operate. This article continues our exploration of...

Advanced therapy medicinal products (ATMPs) are redefining the boundaries of modern medicine. These cutting-edge treatments offer unprecedented opportunities to address complex diseases and deliver life-changing outcomes for patients. Yet, as this field rapidly evolves, so do the challenges—ranging from regulatory frameworks to manufacturing agility. To stay ahead, the industry must embrace...

To deliver meaningful value, a conference must truly reflect the current pulse of the pharmaceutical industry. This is easier said than done, as the sector is undergoing a profound and multifaceted transformation.

In pharma, AI’s biggest challenge isn’t technical, it’s cultural.

2025 marks a significant milestone for the ISPE Argentina Affiliate with its 20th anniversary—commemorating two decades of commitment to excellence, collaboration, and integrity within the Latin American pharmaceutical community.

Laboratory automation in the pharmaceutical industry is rapidly evolving due to increasing regulatory demands and the need for efficiency, flexibility, and data integrity. However, fragmented systems, proprietary protocols, and inconsistent validation frameworks continue to limit progress.

The pharmaceutical industry is at a crossroads. Legacy systems, manual workflows, and paper-heavy processes are slowing down innovation.

P&ID walk-downs are a critical activity during commissioning and qualification (C&Q) turnover, ensuring that physical installations align with the design intent. Traditionally, this process relies on manual checks using printed drawings, which is labor-intensive and prone to human error. Although digital platforms exist across design, engineering, construction and turnover...